APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gene Site-Directed Mutagenesis Services

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Gene Site-Directed Mutagenesis Services Market Analysis and Forecast 2026-2032

11 April 2026202 pages

Choose your research edition.

Industry ResearchGene Site-Directed Mutagenesis Services Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Site-Directed Mutagenesis Services Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Gene Site-Directed Mutagenesis Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Site-Directed Mutagenesis Services Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Gene Site-Directed Mutagenesis Services Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Gene Site-Directed Mutagenesis Services market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Gene Site-Directed Mutagenesis Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Gene Site-Directed Mutagenesis Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Gene Site-Directed Mutagenesis Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Gene Site-Directed Mutagenesis Services is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Gene Site-Directed Mutagenesis Services include Azenta Life Sciences, GenScript, Thermo Fisher Scientific, Charles River Laboratories, Genewiz, Creative Biolabs, NovoPro Bioscience Inc., ACGT, Inc. and Epoch Life Science, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Gene Site-Directed Mutagenesis Services, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gene Site-Directed Mutagenesis Services, also provides the revenue of main regions and countries. Of the upcoming market potential for Gene Site-Directed Mutagenesis Services, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gene Site-Directed Mutagenesis Services revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gene Site-Directed Mutagenesis Services market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Gene Site-Directed Mutagenesis Services revenue, projected growth trends, production technology, application and end-user industry.

Gene Site-Directed Mutagenesis Services Segment by Company

Azenta Life Sciences

GenScript

Thermo Fisher Scientific

Charles River Laboratories

Genewiz

Creative Biolabs

NovoPro Bioscience Inc.

ACGT, Inc.

Epoch Life Science

Eurofins Genomics

NZYtech

Synbio Technologies

Tsingke

GenCefe

Generay

Gene Site-Directed Mutagenesis Services Segment by Type

Synonymous Mutations

Missense Mutation

Nonsense Mutation

Gene Site-Directed Mutagenesis Services Segment by Application

Medical Industry

Biological Research

Others

Gene Site-Directed Mutagenesis Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Site-Directed Mutagenesis Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Site-Directed Mutagenesis Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Site-Directed Mutagenesis Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Gene Site-Directed Mutagenesis Services in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Gene Site-Directed Mutagenesis Services company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gene Site-Directed Mutagenesis Services revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gene Site-Directed Mutagenesis Services Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Synonymous Mutations Major Player Table 3. Missense Mutation Major Player Table 4. Nonsense Mutation Major Player Table 5. Global Gene Site-Directed Mutagenesis Services Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Medical Industry Major Player Table 7. Biological Research Major Player Table 8. Others Major Player Table 9. Gene Site-Directed Mutagenesis Services Industry Trends Table 10. Gene Site-Directed Mutagenesis Services Industry Drivers Table 11. Gene Site-Directed Mutagenesis Services Industry Opportunities and Challenges Table 12. Gene Site-Directed Mutagenesis Services Industry Restraints Table 13. Global Gene Site-Directed Mutagenesis Services Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Gene Site-Directed Mutagenesis Services Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Gene Site-Directed Mutagenesis Services Market Share by Region (2021-2026) Table 16. Global Gene Site-Directed Mutagenesis Services Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Gene Site-Directed Mutagenesis Services Market Share by Region (2027-2032) Table 18. Global Gene Site-Directed Mutagenesis Services Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Gene Site-Directed Mutagenesis Services Revenue Market Share by Players (2021-2026) Table 20. Global Gene Site-Directed Mutagenesis Services Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Gene Site-Directed Mutagenesis Services Key Players Headquarters & Area Served Table 22. Global Gene Site-Directed Mutagenesis Services Players, Product Type & Application Table 23. Global Gene Site-Directed Mutagenesis Services Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Gene Site-Directed Mutagenesis Services by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Gene Site-Directed Mutagenesis Services Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Gene Site-Directed Mutagenesis Services Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Gene Site-Directed Mutagenesis Services Revenue Market Share by Type (2021-2026) Table 30. Global Gene Site-Directed Mutagenesis Services Revenue Market Share by Type (2027-2032) Table 31. Global Gene Site-Directed Mutagenesis Services Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Gene Site-Directed Mutagenesis Services Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Gene Site-Directed Mutagenesis Services Revenue Market Share by Application (2021-2026) Table 35. Global Gene Site-Directed Mutagenesis Services Revenue Market Share by Application (2027-2032) Table 36. Azenta Life Sciences Company Information Table 37. Azenta Life Sciences Business Overview Table 38. Azenta Life Sciences Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Azenta Life Sciences Gene Site-Directed Mutagenesis Services Product Portfolio Table 40. Azenta Life Sciences Recent Development Table 41. GenScript Company Information Table 42. GenScript Business Overview Table 43. GenScript Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. GenScript Gene Site-Directed Mutagenesis Services Product Portfolio Table 45. GenScript Recent Development Table 46. Thermo Fisher Scientific Company Information Table 47. Thermo Fisher Scientific Business Overview Table 48. Thermo Fisher Scientific Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Thermo Fisher Scientific Gene Site-Directed Mutagenesis Services Product Portfolio Table 50. Thermo Fisher Scientific Recent Development Table 51. Charles River Laboratories Company Information Table 52. Charles River Laboratories Business Overview Table 53. Charles River Laboratories Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Charles River Laboratories Gene Site-Directed Mutagenesis Services Product Portfolio Table 55. Charles River Laboratories Recent Development Table 56. Genewiz Company Information Table 57. Genewiz Business Overview Table 58. Genewiz Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Genewiz Gene Site-Directed Mutagenesis Services Product Portfolio Table 60. Genewiz Recent Development Table 61. Creative Biolabs Company Information Table 62. Creative Biolabs Business Overview Table 63. Creative Biolabs Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Creative Biolabs Gene Site-Directed Mutagenesis Services Product Portfolio Table 65. Creative Biolabs Recent Development Table 66. NovoPro Bioscience Inc. Company Information Table 67. NovoPro Bioscience Inc. Business Overview Table 68. NovoPro Bioscience Inc. Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. NovoPro Bioscience Inc. Gene Site-Directed Mutagenesis Services Product Portfolio Table 70. NovoPro Bioscience Inc. Recent Development Table 71. ACGT, Inc. Company Information Table 72. ACGT, Inc. Business Overview Table 73. ACGT, Inc. Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. ACGT, Inc. Gene Site-Directed Mutagenesis Services Product Portfolio Table 75. ACGT, Inc. Recent Development Table 76. Epoch Life Science Company Information Table 77. Epoch Life Science Business Overview Table 78. Epoch Life Science Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Epoch Life Science Gene Site-Directed Mutagenesis Services Product Portfolio Table 80. Epoch Life Science Recent Development Table 81. Eurofins Genomics Company Information Table 82. Eurofins Genomics Business Overview Table 83. Eurofins Genomics Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Eurofins Genomics Gene Site-Directed Mutagenesis Services Product Portfolio Table 85. Eurofins Genomics Recent Development Table 86. NZYtech Company Information Table 87. NZYtech Business Overview Table 88. NZYtech Gene Site-Directed Mutagenesis Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. NZYtech Gene Site-Directed Mutagenesis Services Product Portfolio Table 90. NZYtech Recent Development Table 91. Synbio Technologies Company Information Table 92. Synbio Technologies Business Overview Table 93. Synbio Technologies Gene Site-Directed Mutagenesis Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Synbio Technologies Gene Site-Directed Mutagenesis Services Product Portfolio Table 95. Synbio Technologies Recent Development Table 96. Tsingke Company Information Table 97. Tsingke Business Overview Table 98. Tsingke Gene Site-Directed Mutagenesis Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Tsingke Gene Site-Directed Mutagenesis Services Product Portfolio Table 100. Tsingke Recent Development Table 101. GenCefe Company Information Table 102. GenCefe Business Overview Table 103. GenCefe Gene Site-Directed Mutagenesis Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. GenCefe Gene Site-Directed Mutagenesis Services Product Portfolio Table 105. GenCefe Recent Development Table 106. Generay Company Information Table 107. Generay Business Overview Table 108. Generay Gene Site-Directed Mutagenesis Services Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Generay Gene Site-Directed Mutagenesis Services Product Portfolio Table 110. Generay Recent Development Table 111. North America Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2026) & (US$ Million) Table 112. North America Gene Site-Directed Mutagenesis Services Revenue by Type (2027-2032) & (US$ Million) Table 113. North America Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2026) & (US$ Million) Table 114. North America Gene Site-Directed Mutagenesis Services Revenue by Application (2027-2032) & (US$ Million) Table 115. North America Gene Site-Directed Mutagenesis Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. North America Gene Site-Directed Mutagenesis Services Revenue by Country (2021-2026) & (US$ Million) Table 117. North America Gene Site-Directed Mutagenesis Services Revenue by Country (US$ Million) & (2027-2032) Table 118. Europe Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2026) & (US$ Million) Table 119. Europe Gene Site-Directed Mutagenesis Services Revenue by Type (2027-2032) & (US$ Million) Table 120. Europe Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2026) & (US$ Million) Table 121. Europe Gene Site-Directed Mutagenesis Services Revenue by Application (2027-2032) & (US$ Million) Table 122. Europe Gene Site-Directed Mutagenesis Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 123. Europe Gene Site-Directed Mutagenesis Services Revenue by Country (2021-2026) & (US$ Million) Table 124. Europe Gene Site-Directed Mutagenesis Services Revenue by Country (US$ Million) & (2027-2032) Table 125. China Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2026) & (US$ Million) Table 126. China Gene Site-Directed Mutagenesis Services Revenue by Type (2027-2032) & (US$ Million) Table 127. China Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2026) & (US$ Million) Table 128. China Gene Site-Directed Mutagenesis Services Revenue by Application (2027-2032) & (US$ Million) Table 129. Asia Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2026) & (US$ Million) Table 130. Asia Gene Site-Directed Mutagenesis Services Revenue by Type (2027-2032) & (US$ Million) Table 131. Asia Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2026) & (US$ Million) Table 132. Asia Gene Site-Directed Mutagenesis Services Revenue by Application (2027-2032) & (US$ Million) Table 133. Asia Gene Site-Directed Mutagenesis Services Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Asia Gene Site-Directed Mutagenesis Services Revenue by Region (US$ Million) & (2021-2026) Table 135. Asia Gene Site-Directed Mutagenesis Services Revenue by Region (US$ Million) & (2027-2032) Table 136. SAMEA Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2026) & (US$ Million) Table 137. SAMEA Gene Site-Directed Mutagenesis Services Revenue by Type (2027-2032) & (US$ Million) Table 138. SAMEA Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2026) & (US$ Million) Table 139. SAMEA Gene Site-Directed Mutagenesis Services Revenue by Application (2027-2032) & (US$ Million) Table 140. SAMEA Gene Site-Directed Mutagenesis Services Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. SAMEA Gene Site-Directed Mutagenesis Services Revenue by Country (2021-2026) & (US$ Million) Table 142. SAMEA Gene Site-Directed Mutagenesis Services Revenue by Country (US$ Million) & (2027-2032) Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Gene Site-Directed Mutagenesis Services Image Figure 2. Global Gene Site-Directed Mutagenesis Services Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene Site-Directed Mutagenesis Services Market Size Share 2021 VS 2025 VS 2032 Figure 4. Synonymous Mutations Image Figure 5. Missense Mutation Image Figure 6. Nonsense Mutation Image Figure 7. Global Gene Site-Directed Mutagenesis Services Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Gene Site-Directed Mutagenesis Services Market Size Share 2021 VS 2025 VS 2032 Figure 9. Medical Industry Image Figure 10. Biological Research Image Figure 11. Others Image Figure 12. Global Gene Site-Directed Mutagenesis Services Market Size (US$ Million) & (2021-2032) Figure 13. Global Gene Site-Directed Mutagenesis Services Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Gene Site-Directed Mutagenesis Services Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Gene Site-Directed Mutagenesis Services Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Gene Site-Directed Mutagenesis Services Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Gene Site-Directed Mutagenesis Services Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Gene Site-Directed Mutagenesis Services Revenue Market Share by Type (2021-2032) Figure 20. Global Gene Site-Directed Mutagenesis Services Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Gene Site-Directed Mutagenesis Services Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Gene Site-Directed Mutagenesis Services Revenue Market Share by Application (2021-2032) Figure 23. North America Gene Site-Directed Mutagenesis Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Gene Site-Directed Mutagenesis Services Revenue Share by Type (2021-2032) Figure 25. North America Gene Site-Directed Mutagenesis Services Revenue Share by Application (2021-2032) Figure 26. North America Gene Site-Directed Mutagenesis Services Revenue Share by Country (2021-2032) Figure 27. United States Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Gene Site-Directed Mutagenesis Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Gene Site-Directed Mutagenesis Services Revenue Share by Type (2021-2032) Figure 32. Europe Gene Site-Directed Mutagenesis Services Revenue Share by Application (2021-2032) Figure 33. Europe Gene Site-Directed Mutagenesis Services Revenue Share by Country (2021-2032) Figure 34. Germany Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Gene Site-Directed Mutagenesis Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Gene Site-Directed Mutagenesis Services Revenue Share by Type (2021-2032) Figure 44. China Gene Site-Directed Mutagenesis Services Revenue Share by Application (2021-2032) Figure 45. Asia Gene Site-Directed Mutagenesis Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Gene Site-Directed Mutagenesis Services Revenue Share by Type (2021-2032) Figure 47. Asia Gene Site-Directed Mutagenesis Services Revenue Share by Application (2021-2032) Figure 48. Asia Gene Site-Directed Mutagenesis Services Revenue Share by Region (2021-2032) Figure 49. Japan Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Gene Site-Directed Mutagenesis Services Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Gene Site-Directed Mutagenesis Services Revenue Share by Type (2021-2032) Figure 57. SAMEA Gene Site-Directed Mutagenesis Services Revenue Share by Application (2021-2032) Figure 58. SAMEA Gene Site-Directed Mutagenesis Services Revenue Share by Country (2021-2032) Figure 59. Brazil Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Gene Site-Directed Mutagenesis Services Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Synonymous Mutations
  • Missense Mutation
  • Nonsense Mutation
Applications
  • Medical Industry
  • Biological Research
  • Others
Companies covered
  • Azenta Life Sciences
  • GenScript
  • Thermo Fisher Scientific
  • Charles River Laboratories
  • Genewiz
  • Creative Biolabs
  • NovoPro Bioscience Inc.
  • ACGT, Inc.
  • Epoch Life Science
  • Eurofins Genomics
  • NZYtech
  • Synbio Technologies
  • Tsingke
  • GenCefe
  • Generay

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gene Site-Directed Mutagenesis Services Market by Type
  3. 1.2.1 Global Gene Site-Directed Mutagenesis Services Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Synonymous Mutations
  5. 1.2.3 Missense Mutation
  6. 1.2.4 Nonsense Mutation
  7. 1.3 Gene Site-Directed Mutagenesis Services Market by Application
  8. 1.3.1 Global Gene Site-Directed Mutagenesis Services Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Medical Industry
  10. 1.3.3 Biological Research
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Gene Site-Directed Mutagenesis Services Market Dynamics
  1. 2.1 Gene Site-Directed Mutagenesis Services Industry Trends
  2. 2.2 Gene Site-Directed Mutagenesis Services Industry Drivers
  3. 2.3 Gene Site-Directed Mutagenesis Services Industry Opportunities and Challenges
  4. 2.4 Gene Site-Directed Mutagenesis Services Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Gene Site-Directed Mutagenesis Services Market Perspective (2021-2032)
  2. 3.2 Global Gene Site-Directed Mutagenesis Services Growth Trends by Region
  3. 3.2.1 Global Gene Site-Directed Mutagenesis Services Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gene Site-Directed Mutagenesis Services Market Size by Region (2021-2026)
  5. 3.2.3 Global Gene Site-Directed Mutagenesis Services Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Gene Site-Directed Mutagenesis Services Revenue by Players
  2. 4.1.1 Global Gene Site-Directed Mutagenesis Services Revenue by Players (2021-2026)
  3. 4.1.2 Global Gene Site-Directed Mutagenesis Services Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Gene Site-Directed Mutagenesis Services Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gene Site-Directed Mutagenesis Services Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Gene Site-Directed Mutagenesis Services Key Players Headquarters & Area Served
  7. 4.4 Global Gene Site-Directed Mutagenesis Services Players, Product Type & Application
  8. 4.5 Global Gene Site-Directed Mutagenesis Services Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Gene Site-Directed Mutagenesis Services Market CR5 and HHI
  11. 4.6.3 2025 Gene Site-Directed Mutagenesis Services Tier 1, Tier 2, and Tier 3
5 Gene Site-Directed Mutagenesis Services Market Size by Type
  1. 5.1 Global Gene Site-Directed Mutagenesis Services Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2032)
  3. 5.3 Global Gene Site-Directed Mutagenesis Services Revenue Market Share by Type (2021-2032)
6 Gene Site-Directed Mutagenesis Services Market Size by Application
  1. 6.1 Global Gene Site-Directed Mutagenesis Services Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2032)
  3. 6.3 Global Gene Site-Directed Mutagenesis Services Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Azenta Life Sciences
  2. 7.1.1 Azenta Life Sciences Company Information
  3. 7.1.2 Azenta Life Sciences Business Overview
  4. 7.1.3 Azenta Life Sciences Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Azenta Life Sciences Gene Site-Directed Mutagenesis Services Product Portfolio
  6. 7.1.5 Azenta Life Sciences Recent Developments
  7. 7.2 GenScript
  8. 7.2.1 GenScript Company Information
  9. 7.2.2 GenScript Business Overview
  10. 7.2.3 GenScript Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  11. 7.2.4 GenScript Gene Site-Directed Mutagenesis Services Product Portfolio
  12. 7.2.5 GenScript Recent Developments
  13. 7.3 Thermo Fisher Scientific
  14. 7.3.1 Thermo Fisher Scientific Company Information
  15. 7.3.2 Thermo Fisher Scientific Business Overview
  16. 7.3.3 Thermo Fisher Scientific Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Thermo Fisher Scientific Gene Site-Directed Mutagenesis Services Product Portfolio
  18. 7.3.5 Thermo Fisher Scientific Recent Developments
  19. 7.4 Charles River Laboratories
  20. 7.4.1 Charles River Laboratories Company Information
  21. 7.4.2 Charles River Laboratories Business Overview
  22. 7.4.3 Charles River Laboratories Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Charles River Laboratories Gene Site-Directed Mutagenesis Services Product Portfolio
  24. 7.4.5 Charles River Laboratories Recent Developments
  25. 7.5 Genewiz
  26. 7.5.1 Genewiz Company Information
  27. 7.5.2 Genewiz Business Overview
  28. 7.5.3 Genewiz Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Genewiz Gene Site-Directed Mutagenesis Services Product Portfolio
  30. 7.5.5 Genewiz Recent Developments
  31. 7.6 Creative Biolabs
  32. 7.6.1 Creative Biolabs Company Information
  33. 7.6.2 Creative Biolabs Business Overview
  34. 7.6.3 Creative Biolabs Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Creative Biolabs Gene Site-Directed Mutagenesis Services Product Portfolio
  36. 7.6.5 Creative Biolabs Recent Developments
  37. 7.7 NovoPro Bioscience Inc.
  38. 7.7.1 NovoPro Bioscience Inc. Company Information
  39. 7.7.2 NovoPro Bioscience Inc. Business Overview
  40. 7.7.3 NovoPro Bioscience Inc. Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  41. 7.7.4 NovoPro Bioscience Inc. Gene Site-Directed Mutagenesis Services Product Portfolio
  42. 7.7.5 NovoPro Bioscience Inc. Recent Developments
  43. 7.8 ACGT, Inc.
  44. 7.8.1 ACGT, Inc. Company Information
  45. 7.8.2 ACGT, Inc. Business Overview
  46. 7.8.3 ACGT, Inc. Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  47. 7.8.4 ACGT, Inc. Gene Site-Directed Mutagenesis Services Product Portfolio
  48. 7.8.5 ACGT, Inc. Recent Developments
  49. 7.9 Epoch Life Science
  50. 7.9.1 Epoch Life Science Company Information
  51. 7.9.2 Epoch Life Science Business Overview
  52. 7.9.3 Epoch Life Science Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Epoch Life Science Gene Site-Directed Mutagenesis Services Product Portfolio
  54. 7.9.5 Epoch Life Science Recent Developments
  55. 7.10 Eurofins Genomics
  56. 7.10.1 Eurofins Genomics Company Information
  57. 7.10.2 Eurofins Genomics Business Overview
  58. 7.10.3 Eurofins Genomics Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Eurofins Genomics Gene Site-Directed Mutagenesis Services Product Portfolio
  60. 7.10.5 Eurofins Genomics Recent Developments
  61. 7.11 NZYtech
  62. 7.11.1 NZYtech Company Information
  63. 7.11.2 NZYtech Business Overview
  64. 7.11.3 NZYtech Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  65. 7.11.4 NZYtech Gene Site-Directed Mutagenesis Services Product Portfolio
  66. 7.11.5 NZYtech Recent Developments
  67. 7.12 Synbio Technologies
  68. 7.12.1 Synbio Technologies Company Information
  69. 7.12.2 Synbio Technologies Business Overview
  70. 7.12.3 Synbio Technologies Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Synbio Technologies Gene Site-Directed Mutagenesis Services Product Portfolio
  72. 7.12.5 Synbio Technologies Recent Developments
  73. 7.13 Tsingke
  74. 7.13.1 Tsingke Company Information
  75. 7.13.2 Tsingke Business Overview
  76. 7.13.3 Tsingke Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Tsingke Gene Site-Directed Mutagenesis Services Product Portfolio
  78. 7.13.5 Tsingke Recent Developments
  79. 7.14 GenCefe
  80. 7.14.1 GenCefe Company Information
  81. 7.14.2 GenCefe Business Overview
  82. 7.14.3 GenCefe Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  83. 7.14.4 GenCefe Gene Site-Directed Mutagenesis Services Product Portfolio
  84. 7.14.5 GenCefe Recent Developments
  85. 7.15 Generay
  86. 7.15.1 Generay Company Information
  87. 7.15.2 Generay Business Overview
  88. 7.15.3 Generay Gene Site-Directed Mutagenesis Services Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Generay Gene Site-Directed Mutagenesis Services Product Portfolio
  90. 7.15.5 Generay Recent Developments
8 North America
  1. 8.1 North America Gene Site-Directed Mutagenesis Services Revenue (2021-2032)
  2. 8.2 North America Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2032)
  3. 8.2.1 North America Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2026)
  4. 8.2.2 North America Gene Site-Directed Mutagenesis Services Revenue by Type (2027-2032)
  5. 8.3 North America Gene Site-Directed Mutagenesis Services Revenue Share by Type (2021-2032)
  6. 8.4 North America Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2032)
  7. 8.4.1 North America Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2026)
  8. 8.4.2 North America Gene Site-Directed Mutagenesis Services Revenue by Application (2027-2032)
  9. 8.5 North America Gene Site-Directed Mutagenesis Services Revenue Share by Application (2021-2032)
  10. 8.6 North America Gene Site-Directed Mutagenesis Services Revenue by Country
  11. 8.6.1 North America Gene Site-Directed Mutagenesis Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Gene Site-Directed Mutagenesis Services Revenue by Country (2021-2026)
  13. 8.6.3 North America Gene Site-Directed Mutagenesis Services Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Gene Site-Directed Mutagenesis Services Revenue (2021-2032)
  2. 9.2 Europe Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2032)
  3. 9.2.1 Europe Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2026)
  4. 9.2.2 Europe Gene Site-Directed Mutagenesis Services Revenue by Type (2027-2032)
  5. 9.3 Europe Gene Site-Directed Mutagenesis Services Revenue Share by Type (2021-2032)
  6. 9.4 Europe Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2032)
  7. 9.4.1 Europe Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2026)
  8. 9.4.2 Europe Gene Site-Directed Mutagenesis Services Revenue by Application (2027-2032)
  9. 9.5 Europe Gene Site-Directed Mutagenesis Services Revenue Share by Application (2021-2032)
  10. 9.6 Europe Gene Site-Directed Mutagenesis Services Revenue by Country
  11. 9.6.1 Europe Gene Site-Directed Mutagenesis Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Gene Site-Directed Mutagenesis Services Revenue by Country (2021-2026)
  13. 9.6.3 Europe Gene Site-Directed Mutagenesis Services Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Gene Site-Directed Mutagenesis Services Revenue (2021-2032)
  2. 10.2 China Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2032)
  3. 10.2.1 China Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2026)
  4. 10.2.2 China Gene Site-Directed Mutagenesis Services Revenue by Type (2027-2032)
  5. 10.3 China Gene Site-Directed Mutagenesis Services Revenue Share by Type (2021-2032)
  6. 10.4 China Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2032)
  7. 10.4.1 China Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2026)
  8. 10.4.2 China Gene Site-Directed Mutagenesis Services Revenue by Application (2027-2032)
  9. 10.5 China Gene Site-Directed Mutagenesis Services Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gene Site-Directed Mutagenesis Services Revenue (2021-2032)
  2. 11.2 Asia Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2032)
  3. 11.2.1 Asia Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2026)
  4. 11.2.2 Asia Gene Site-Directed Mutagenesis Services Revenue by Type (2027-2032)
  5. 11.3 Asia Gene Site-Directed Mutagenesis Services Revenue Share by Type (2021-2032)
  6. 11.4 Asia Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2032)
  7. 11.4.1 Asia Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2026)
  8. 11.4.2 Asia Gene Site-Directed Mutagenesis Services Revenue by Application (2027-2032)
  9. 11.5 Asia Gene Site-Directed Mutagenesis Services Revenue Share by Application (2021-2032)
  10. 11.6 Asia Gene Site-Directed Mutagenesis Services Revenue by Country
  11. 11.6.1 Asia Gene Site-Directed Mutagenesis Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Gene Site-Directed Mutagenesis Services Revenue by Country (2021-2026)
  13. 11.6.3 Asia Gene Site-Directed Mutagenesis Services Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gene Site-Directed Mutagenesis Services Revenue (2021-2032)
  2. 12.2 SAMEA Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Gene Site-Directed Mutagenesis Services Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Gene Site-Directed Mutagenesis Services Revenue by Type (2027-2032)
  5. 12.3 SAMEA Gene Site-Directed Mutagenesis Services Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Gene Site-Directed Mutagenesis Services Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Gene Site-Directed Mutagenesis Services Revenue by Application (2027-2032)
  9. 12.5 SAMEA Gene Site-Directed Mutagenesis Services Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Gene Site-Directed Mutagenesis Services Revenue by Country
  11. 12.6.1 SAMEA Gene Site-Directed Mutagenesis Services Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Gene Site-Directed Mutagenesis Services Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Gene Site-Directed Mutagenesis Services Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst